UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934
Date of Report (Date of earliest event reported): June 17, 2004
HEMACARE CORPORATION
(Exact name of registrant as specified in its charter)
California
(State or other jurisdiction of incorporation)
000-15223 95-3280412
(Commission File No.) (I.R.S. Employer Identification No.)
21101 Oxnard Street
Woodland Hills, CA 91367
(Address of principal executive offices)(Zip Code)
Registrant's telephone number, including area code: (818) 226-
1968
-1-
2
ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE
The text of a press release dated June 17, 2004, issued by
HemaCare Corporation ("HemaCare") announcing an investigational
site agreement with Otsuka America Pharmaceutical and the
termination of a blood center management contract with Dartmouth
Hitchcock Hospital, is attached as Exhibit 99.1 hereto and is
incorporated by reference herein.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS
(c) Exhibits
Exhibit Number Description
-------------- ------------------------------------------------
99.1 Press Release issued by HemaCare, dated June 17,
2004
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
Date: June 18, 2004 HEMACARE CORPORATION
By: /s/ Judi Irving
__________________________
Judi Irving,
Chief Executive Officer
-2-
3
EXHIBIT INDEX
Exhibit Number Description
-------------- ---------------------------------------------
99.1 Press Release issued by HemaCare, dated
June 17, 2004
-3-